Incorporation of indomethacin nanoparticles into 3-D ordered macroporous silica for enhanced dissolution and reduced gastric irritancy

被引:62
作者
Hu, Yanchen [1 ]
Zhi, Zhuangzhi [2 ]
Wang, Tianyi [1 ]
Jiang, Tongying [1 ]
Wang, Siling [1 ]
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmaceut, Shenyang, Peoples R China
[2] Shenyang Pharmaceut Univ, Dept Phys, Shenyang, Peoples R China
基金
中国国家自然科学基金;
关键词
3-D ordered macroporous silica; Drug nanoparticles; In vitro dissolution; Gastric damage; POORLY SOLUBLE DRUGS; AMORPHOUS INDOMETHACIN; NANOCRYSTALS; FORMULATION; PERFORMANCE; IMPROVEMENT; SOLUBILITY; MIXTURES; CARBON;
D O I
10.1016/j.ejpb.2011.07.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, we exploited for the first time the potential of 3-D ordered macroporous (3DOM) silica as matrix for drug nanoparticles, in order to obtain proper control over drug particle size in the sub-micrometer range, enhance the dissolution rate, and reduce gastric damage. 3DOM silica matrix with 3-D spherical pores of 200 nm was successfully created and then loaded with IMC nanoparticles at various drug-silica ratios. A rapid release profile for IMC nanoparticle formulations was achieved in comparison with microsized IMC and a commercial capsule, which could be attributed to both increase in the specific surface area and decrease in the crystallinity of IMC, as well as the hydrophilic surface and the interconnected pore networks of 3DOM silica. Reduced gastric damage of IMC was demonstrated, and the protective effect may arise from the reduction in drug particle size as well as encapsulation effect of 3DOM silica. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:544 / 551
页数:8
相关论文
共 35 条
[1]   Enhancement of the dissolution of indomethacin in interactive mixtures using added fine lactose [J].
Allahham, Ayman ;
Stewart, Peter J. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 67 (03) :732-742
[2]   Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate [J].
Ambrogi, V. ;
Perioli, L. ;
Marmottini, F. ;
Giovagnoli, S. ;
Esposito, M. ;
Rossi, C. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 32 (03) :216-222
[3]   JEJUNAL-ABSORPTION, PHARMACOLOGICAL ACTIVITY, AND PHARMACOKINETIC EVALUATION OF INDOMETHACIN-LOADED POLY(D,L-LACTIDE) AND POLY(ISOBUTYL-CYANOACRYLATE) NANOCAPSULES IN RATS [J].
AMMOURY, N ;
FESSI, H ;
DEVISSAGUET, JP ;
DUBRASQUET, M ;
BENITA, S .
PHARMACEUTICAL RESEARCH, 1991, 8 (01) :101-105
[4]  
CA, 2001, DRUG DELIV, V46, P3
[5]  
Dokmeci D, 2005, PHARMACOL REP, V57, P481
[6]   Drug solubility: how to measure it, how to improve it - Preface [J].
Dressman, Jennifer ;
Reppas, Christos .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :531-532
[7]   Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers [J].
Friedrich, H ;
Fussnegger, B ;
Kolter, K ;
Bodmeier, R .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 62 (02) :171-177
[8]   Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system [J].
Gao, Lei ;
Zhang, Dianrui ;
Chen, Minghui .
JOURNAL OF NANOPARTICLE RESEARCH, 2008, 10 (05) :845-862
[9]  
GARY PC, 1995, INT J PHARMACEUT, P309
[10]   Oral lipid-based formulations [J].
Hauss, David J. .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :667-676